



Natco Pharma Limited

Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034.
Telangana, INDIA. Tel : +91 40 23547532, Fax : +91 40 23548243
CIN : L24230TG1981PLC003201, www.natcopharma.co.in

June 10, 2020

Corporate Relationship Department
M/s. BSE Ltd
Dalal Street, Fort
Mumbai- 400 001

Manager – Listing
M/s. National Stock Exchange of India Ltd
“Exchange Plaza”, Bandra – Kurla Complex
Bandra (E) **Mumbai -400 051**

Scrip Code: 524816

Scrip Code: NATCOPHARM

Dear Sir

Sub: - Earning call for Q4 and year ended FY20

The Company will host an Earnings Call with Investors / Analysts at **11.00 a.m. IST on June 18, 2020** to disseminate Financial Results of the company for the quarter and year ended March 31, 2020.

A Copy of the same is enclosed for your ready reference

Thanking you

Yours faithfully
For NATCO Pharma Limited

ADINARAYAN
A MADINEEDI

M Adinarayana
Company Secretary &
Vice President (Legal & Corp Affairs)



Axis House, C-2, Wadia International Centre, P.B Marg. Worli, Mumbai 400 025 (India)



Natco Pharma

Q4FY20 Earnings Call on 18th June 2020
hosted by Axis Capital Limited

We are pleased to host, on behalf of Natco Pharma, a **conference call for analysts and investors on Thursday, 18th June 2020**, following the announcement of financial results for the fourth quarter ended March 2020.

The call will be initiated with a brief management discussion on the Q4FY20 earnings performance followed by an interactive Question & Answer session. The management will be represented by

- ❑ **Mr. Rajeev Nannapaneni** : Vice Chairman and Chief Executive Officer
- ❑ **Mr. Rajesh Chebiyam** : Vice President – Acquisitions, Institutional Investor Management and Corporate Communications

Details of conference call

Date	: Thursday, 18 th June 2020
Time	: 11:00 AM IST 1:30 PM HK/SG 6:30 AM UK 12:30 AM USA
Call leader	: Mr. Prakash Agarwal, Axis Capital

Country	Dial in numbers
Primary number	+91 22 6280 1145 / + 91 22 7115 8046
India Local	+91 7045671221 (available all over India)
International Dial in	
- Hong Kong	800 964 448
- Singapore	800 101 2045
- U K	0 808 101 1573
- USA	1 866 746 2133

For further information please contact:

Prakash Agarwal

Dy Head – Research | Executive Director – Pharma
Institutional Equity Research
Axis Capital Limited
Direct: +91 22 4325 1145
Board: +91 22 4325 2525
Mobile: +91 9820534334
Email: prakash.agarwal@axiscap.in